Angiographic and platelet reactivity outcomes with prasugrel 60 mg pretreatment and clopidogrel 600 mg pretreatment in primary percutaneous coronary intervention

@article{Li2012AngiographicAP,
  title={Angiographic and platelet reactivity outcomes with prasugrel 60 mg pretreatment and clopidogrel 600 mg pretreatment in primary percutaneous coronary intervention},
  author={Yiding Li and B. C. Tai and Winnie Sia and Qian-Hui Phua and Mark A. Richards and Adrian Low and Mark Y. Chan and Swee-Guan Teo and Teresa Sim and Chi-Hang Lee and Matthew T. Roe and T. E. Dominic Yeo and H H Tan and Mark Y Chan},
  journal={Journal of Thrombosis and Thrombolysis},
  year={2012},
  volume={34},
  pages={499-505}
}
Pretreatment with 60 mg of prasugrel is more effective than 300 mg of clopidogrel in reducing thrombotic complications with primary percutaneous coronary intervention (PCI). We compared angiographic outcomes and platelet reactivity between treatment with 60 mg of prasugrel and 600 mg of clopidogrel administered before primary PCI. In this single centre non-randomized study, 65 consecutive Asian patients with ST-elevation myocardial infarction (STEMI) received 60 mg of prasugrel before primary… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 17 references

Functional significance and differential prevalence of CYP 2 C 19 and PON 1 polymorphisms regulating clopidogrel bioactivation in Chinese , Malay and Indian subjects

MY Chan, K Tan, Tan H-C
Pharmacogenomics • 2012